Schizophrenia and related disorders during mid- to late-life (R01, R21 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications that will advance translational research to better understand the emergence, trajectory, and outcomes of schizophrenia and related psychotic disorders in mid- to late-life, and to identify targets for future development of prevention and treatment interventions.

This NOFO uses the R01 grant mechanism, while the companion NOFO (PAR-24-026), uses the R21 mechanism. Investigators proposing high risk/high reward projects that lack preliminary data may be more appropriate for the R21 mechanism.

Deadlines:

  • Letter of Intent: 30 days prior to the application due date
  • R01 Due Dates: ¬†Feb. 5, June 5, Oct. 5
  • R21 Due Dates: Feb. 16, June 16, Oct. 16

PAR-24-023 Expiration Date September 08, 2026

Agency Website

Areas of Interest

This NOFO is intended to support research designed to identify the neurobiological, behavioral, psychosocial, and environmental mechanisms underlying the onset, trajectory, and outcome of schizophrenia and related psychotic disorders in mid- to late-life, with consideration for the identification of novel targets for future development of prevention and intervention efforts. Studies that leverage concepts, methods, and findings emerging from geroscience research on mechanisms of normative and pathological aging as predictors of risk, trajectory, and outcome of schizophrenia and related psychotic disorders in mid- to late-life are encouraged.

Research must target populations in the mid- to late-life age range or mid-late life stages, but relevant comparison populations may include those who are younger if scientifically justified.

Funding Type

Grant

Eligibility

Faculty

Category

Medical
Medical - Clinical Science
Medical - Translational

External Deadline

October 5, 2023